JMP Securities Maintains Market Outperform on Macrogenics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan maintains a Market Outperform rating on Macrogenics (NASDAQ:MGNX) but lowers the price target from $16 to $8.
July 31, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JMP Securities has maintained its Market Outperform rating on Macrogenics but has significantly lowered the price target from $16 to $8.
The significant reduction in the price target from $16 to $8 by JMP Securities suggests a more cautious outlook on Macrogenics' future performance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100